Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity.

scientific article published on 21 February 2014

Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1021/JA500053X
P932PMC publication ID3985699
P698PubMed publication ID24517363
P5875ResearchGate publication ID260148151

P50authorZhihong PengQ57384124
Leticia I LlarrullQ64514313
Mayland ChangQ89378129
Katerina Zorina-LichtenwalterQ116455839
Malika KumarasiriQ118431448
Erika LeemansQ118431699
Edward SpinkQ118431712
Derong DingQ118431724
Sebastian A TesteroQ118431740
Shahriar MobasheryQ28316904
Mark A. SuckowQ41543478
P2093author name stringWei Song
Hualiang Pi
Elena Lastochkin
Marc A Boudreau
Peter I O'Daniel
Takao Yamaguchi
Nuno T Antunes
Valerie A Schroeder
William R Wolter
Mana Espahbodi
Sergei Vakulenko
P2860cites workEmergence of daptomycin resistance in Enterococcus faecium during daptomycin therapyQ42708842
Linezolid resistance in a clinical isolate of Staphylococcus aureusQ43690311
Health care-associated invasive MRSA infections, 2005-2008.Q44110236
The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureusQ44958662
A practical synthesis of nitrocefinQ45206061
Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003.Q46878727
Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins.Q53981730
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureusQ59374940
The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA)Q24530652
Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureusQ27639852
ZINC--a free database of commercially available compounds for virtual screeningQ27656255
How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological functionQ27680124
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycinQ28268465
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaQ29616084
Invasive methicillin-resistant Staphylococcus aureus infections in the United StatesQ29616087
Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.Q30228250
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitorsQ33339829
Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathwayQ33767185
Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005Q33877838
Resistance studies with daptomycinQ33982318
Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococciQ33982606
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunityQ33984936
Antibiotics: where did we go wrong?Q36022317
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureusQ36381504
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaQ36382134
The penicillin-binding proteins: structure and role in peptidoglycan biosynthesisQ37081708
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.Q37392891
BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteinsQ39470055
Possible physiological functions of penicillin-binding proteins in Staphylococcus aureusQ39834475
P4510describes a project that usesImageQuantQ112270642
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectgram-positive bacteriaQ857288
P1104number of pages9
P304page(s)3664-3672
P577publication date2014-02-21
P1433published inJournal of the American Chemical SocietyQ898902
P1476titleDiscovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity
P478volume136

Reverse relations

cites work (P2860)
Q640725091,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer
Q40742571A Vancomycin Derivative with a Pyrophosphate-Binding Group: A Strategy to Combat Vancomycin-Resistant Bacteria
Q58799329Activities of Oxadiazole Antibacterials against Staphylococcus aureus and Other Gram-Positive Bacteria
Q51311450Computer-Aided Drug Design Methods.
Q28821040Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine)
Q28822179Endless Resistance. Endless Antibiotics?
Q36167152Exploration of the structure-activity relationship of 1,2,4-oxadiazole antibiotics
Q26749531Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New Antibacterials
Q33659793In Vitro Evaluations and In Vivo Toxicity and Efficacy Studies of MFM501 against MRSA.
Q37203885In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams
Q92682023Ligands and Receptors with Broad Binding Capabilities Have Common Structural Characteristics: An Antibiotic Design Perspective
Q38952894Membrane Disruption and Enhanced Inhibition of Cell-Wall Biosynthesis: A Synergistic Approach to Tackle Vancomycin-Resistant Bacteria.
Q34298926Mutations in mmpL and in the cell wall stress stimulon contribute to resistance to oxadiazole antibiotics in methicillin-resistant Staphylococcus aureus
Q50100988Novel bis-cyclic guanidines as potent membrane-active antibacterial agents with therapeutic potential.
Q38712471One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams
Q38232037Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus.
Q60304005Reactions of 3-(-substituted-phenyl)-5-chloromethyl-1,2,4-oxadiazoles with KCN leading to acetonitriles and alkanes via a non-reductive decyanation pathway
Q90412680Structure-Activity Relationship for the Oxadiazole Class of Antibacterials
Q41543426Structure-activity relationship for the oxadiazole class of antibiotics.
Q93013199Synergistic anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and absolute stereochemistry of 7,8-dideoxygriseorhodin C
Q36248215Synthesis and evaluation of 1,2,4-triazolo[1,5-a]pyrimidines as antibacterial agents against Enterococcus faecium
Q41686055Tackling vancomycin-resistant bacteria with 'lipophilic-vancomycin-carbohydrate conjugates'.
Q49970485The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.
Q39573499The Natural Product Essramycin and Three of Its Isomers Are Devoid of Antibacterial Activity
Q38848065The oxadiazole antibacterials
Q36848213Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials
Q38846432Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury

Search more.